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Background: Bosentan therapy improves symptoms in ES patients but few studies have addressed the change of cardiac function after treatment. 
This study examined the long-term effect of bosentan therapy on cardiac function and its relation to symptomatic benefits in patients with 
Eisenmenger syndrome (ES).
Methods: We prospectively studied 23 consecutive adult ES patients (aged 31± 12 years) before and at 23 ± 9 months after bosentan therapy. 
Measurements of pulmonary arterial systolic pressure, RV and LV myocardial performance index (MPI), tricuspid and lateral mitral annular pulsed-
wave tissue Doppler systolic (Sa) and early diastolic (Ea) long axis motions were made. Patients’ New York Heart Association (NYHA) functional class, 
6-minute walk distance (6MWD) and systemic arterial oxygen saturations (SaO2) were also recorded.
Results: Pulmonary arterial systolic pressure dropped (118 ± 22 to 111 ± 19, p=0.044), NYHA functional class, 6MWD and SaO2 all improved (3.2 
± 0.4 to 2.4 ± 0.5, 286 ± 129m to 395 ± 120m and 84.6 ± 6.5% to 88.8 ± 3.9%, all p<0.01) after therapy, There was also significant improvement 
in RV MPI (by 23.9%, 0.46 ± 0.15 to 0.35 ± 0.09) and biventricular long axis function (tricuspid Sa and Ea: 6.7 ± 1.5 to 8.8 ± 1.7cm/s and 5.7 
± 1.3 to 7.0 ± 1.2cm/s; lateral Sa and Ea 6.8 ± 1.3 to 8.4 ± 1.5cm/s and 7.6 ± 2.0 to 8.5 ± 2.1cm/s, p<0.05 for all). Post-therapy RV MPI was 
moderately correlated with PASP and 6MWD (RV MPI vs. PASP r=0.63; RV MPI vs. 6MWD r=-0.54, p<0.05 for all,)
Conclusion: Bosentan therapy results in long term improvement of pulmonary hypertension and RV function in ES patients. These hemodynamic 
improvements should provide insights on the symptomatic benefits gained in these patients.
